OS Therapies (OSTX) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually, allowing shareholders to vote and submit questions online, with the same rights as an in-person meeting.

• Shareholders will vote on the election of six directors, approval of a major stock issuance, amendments to the charter and incentive plan, a shareholder rights agreement, auditor ratification, and other business.

• The board recommends voting in favor of all proposals and has provided detailed proxy materials online for review.

Voting matters and shareholder proposals

• Proposals include electing six directors, issuing shares to Ayala Pharmaceuticals, amending the charter to increase authorized shares, amending the incentive plan, adopting a shareholder rights agreement, and ratifying the auditor.

• The issuance proposal relates to a HER2 asset purchase, with shares or warrants to be issued to Ayala, potentially diluting existing shareholders.

• The charter amendment would increase authorized common stock from 50 million to 150 million shares.

• The plan amendment increases shares available under the incentive plan from 4 million to 10 million and raises individual grant limits.

• The rights agreement proposal authorizes the board to implement a plan to deter hostile takeovers by issuing rights to existing shareholders.

• Shareholder proposals for the next annual meeting must be submitted in accordance with SEC rules and company bylaws.

Board of directors and corporate governance

• The board consists of six members, with only the CEO not considered independent.

• Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.

• The board prioritizes professional accomplishment, relevant expertise, and collaborative culture in director selection.

• Directors are encouraged to attend the annual meeting, and a process exists for shareholders to communicate with the board.

• A code of business conduct and ethics is in place, and an insider trading policy is planned for adoption in 2025.